ARINA-1

Phase 3Small molecule

RRenovion, Inc.

ARINA-1 is one of 57 small molecule programs targeting Bronchiolitis Obliterans. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchiolitis ObliteransActive, not recruiting

Cystic FibrosisActive, not recruiting

Bronchiolitis ObliteransPhase 3

Active, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

ARINA-1

RRenovion, Inc.

Phase 3

1 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Advil

KKenvue Brands

Preclinical

1 9

Serevent

GGlaxo Dba Glaxosmithkline

Preclinical

1 10

Tums

Otsuka

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Bronchiolitis Obliterans

NCT05654922

Clinical

Trials by Indication[1]

Bronchiolitis Obliterans1 trial

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

Recruiting·RRenovion, Inc.·Phase 3·NCT05654922·100 enrolled

Safety and Efficacy1 trial

An Investigator-initiated Study to Evaluate Safety and Efficacy of ARINA-1 in People With a Tracheostomy

Withdrawn·MMatthew Bruehl·Phase 1·NCT05658029

Cystic Fibrosis1 trial

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Completed·RRenovion, Inc.·Phase 2·NCT05495243·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ARINA-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARINA-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARINA-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Renovion, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRenovion, Inc.

ARINA-1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Bronchiolitis Obliterans1 trial

Safety and Efficacy1 trial

Cystic Fibrosis1 trial

References

Drug Info

Quick Facts

Related News